Ad. Roberts et al., Alterations in serum levels of lipids and lipoproteins with indinavir therapy for human immunodeficiency virus-infected patients, CLIN INF D, 29(2), 1999, pp. 441-443
Alterations in lipid metabolism have been associated with the use of protea
se inhibitors. Sequential lipid analyses were performed on serum samples fr
om human immunodeficiency virus-infected antiretroviral-naive patients who
received indinavir in combination with two nucleoside reverse transcriptase
inhibitors, Serum levels of cholesterol, triglycerides, high-density lipop
roteins (HDLs), and low-density lipoproteins (LDLs) were measured at baseli
ne and at periodic intervals. After 48 weeks of indinavir therapy, mean ser
um levels a SD rose as follows: cholesterol, from 167.2 +/- 36.0 to 206.3 /- 32.4 mg/dL (P < .0005); triglycerides, from 110.4 +/- 47.5 to 158.4 +/-
72.5 mg/dL (P < .0101); and LDLs, from 106.6 +/- 35.1 to 136.1 +/- 31.6 mg/
dL (P = .0029), There was no significant change in the serum HDL fraction.
Mean serum lipoprotein (a) levels +/- SD rose from 6.5 +/- 1.4 to 9.6 +/- 2
.0 mg/dL after 30 weeks (P = .0695), Potential mechanisms for the noted inc
reases include alterations in serum lipoprotein lipase activity or changes
in hepatic lipid metabolism. The clinical significance of these changes rem
ains to be determined.